Amphastar Pharmaceuticals AMPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $720.53M+0.1% | $719.89M-0.5% | $723.31M+0.1% | $722.68M-1.1% | $730.66M-0.2% | ||
| $379.4M+4.3% | $363.83M-0.7% | $366.27M+1.1% | $362.35M+0.2% | $361.65M+1.0% | ||
| $341.13M-4.2% | $356.06M-0.3% | $357.04M-0.9% | $360.33M-2.4% | $369.01M-1.3% | ||
| 47.3%-2.1pp | 49.5%+0.1pp | 49.4%-0.5pp | 49.9%-0.6pp | 50.5%-0.6pp | ||
| $92.49M+7.7% | $85.84M+6.4% | $80.67M+1.6% | $79.4M+3.2% | $76.97M+4.1% | ||
| $43.95M+0.1% | $43.89M-0.3% | $44.03M+6.0% | $41.52M+3.0% | $40.3M+6.6% | ||
| $87.96M+2.4% | $85.93M+4.3% | $82.39M+42.7% | $57.75M+1.2% | $57.04M+0.6% | ||
| $224.39M+4.1% | $215.65M+4.1% | $207.09M+15.9% | $178.66M+2.5% | $174.3M+3.5% | ||
| $116.74M-16.9% | $140.4M-6.4% | $149.94M-17.5% | $181.67M-6.7% | $194.7M-5.2% | ||
| 16.2%-3.3pp | 19.5%-1.2pp | 20.7%-4.4pp | 25.1%-1.5pp | 26.6%-1.4pp | ||
| $25.75M+1.0% | $25.48M+0.8% | $25.28M-1.6% | $25.69M-8.3% | $28.02M-7.7% | ||
| -$13.93M+17.0% | -$16.78M-17.6% | -$14.27M+28.0% | -$19.83M+9.7% | -$21.95M-40.2% | ||
| $102.81M-16.8% | $123.62M-8.9% | $135.67M-16.2% | $161.84M-6.3% | $172.75M-9.0% | ||
| $23.59M-7.6% | $25.53M+6.2% | $24.04M-11.4% | $27.13M-12.8% | $31.12M+4.9% | ||
| $79.23M-19.2% | $98.09M-12.1% | $111.63M-17.1% | $134.71M-4.9% | $141.63M-11.2% | ||
| 11%-2.6pp | 13.6%-1.8pp | 15.4%-3.2pp | 18.6%-0.7pp | 19.4%-2.4pp | ||
| $1.66-18.2% | $2.03-10.2% | $2.26-15.4% | $2.67-3.3% | $2.76-9.8% | ||
| $174.17M-11.6% | $197.1M-4.2% | $205.73M-13.1% | $236.73M-4.7% | $248.3M-3.9% | ||
| 24.2%-3.2pp | 27.4%-1.1pp | 28.4%-4.3pp | 32.8%-1.2pp | 34%-1.3pp | ||
| $116.74M-16.9% | $140.4M-6.4% | $149.94M-17.5% | $181.67M-6.7% | $194.7M-5.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amphastar Pharmaceuticals's revenue?
- Amphastar Pharmaceuticals (AMPH) generated $720.5M in revenue over the trailing twelve months, down 1.4% year over year.
- Is Amphastar Pharmaceuticals profitable?
- Amphastar Pharmaceuticals reported $79.2M in net income over the trailing twelve months, a 11.0% net margin.
- What are Amphastar Pharmaceuticals's profit margins?
- Gross margin is 47.3% and operating margin is 16.2%, with a 11.0% net margin.
- What is Amphastar Pharmaceuticals's earnings per share?
- Amphastar Pharmaceuticals's diluted EPS over the trailing twelve months is $1.66.
- Where does Amphastar Pharmaceuticals's income statement data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
